Cited 16 times in
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 이정윤 | - |
dc.date.accessioned | 2019-12-18T01:11:51Z | - |
dc.date.available | 2019-12-18T01:11:51Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173412 | - |
dc.description.abstract | A pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer has been started in Korea. Archival tumor samples were tested for HRD and PD-L1 status. Treatment arms will be allocated according to the test results. For HRD+ patients, we tested the synergistic effects of olaparib and other agents; treatment arms will randomly be allocated. (Arm 1: olaparib and cediranib; Arm 2: olaparib and durvalumab). For HRD- patients, we tested the role of biomarker-driven immunotherapy according to PD-L1 expression (Arm 3: durvalumab and chemotherapy in patients with high PD-L1 expression; Arm 4: durvalumab, tremelimumab, and chemotherapy in patients with low PD-L1 expression). Sixty-eight patients will be included from three Korean institutions within 1 year. The primary endpoint is the response rate according to RECIST 1.1 (6 months after treatment initiation). This trial has been registered with clinicaltrials.gov, and the registration number is NCT03699449. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Ju Yeon Yi | - |
dc.contributor.googleauthor | Hyun-Soo Kim | - |
dc.contributor.googleauthor | June Lim | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Byoung Ho Nam | - |
dc.contributor.googleauthor | Hee Seung Kim | - |
dc.contributor.googleauthor | Jae Weon Kim | - |
dc.contributor.googleauthor | Chel Hun Choi | - |
dc.contributor.googleauthor | Byoung-Gie Kim | - |
dc.identifier.doi | 10.1093/jjco/hyz085 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A04638 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 31671191 | - |
dc.identifier.url | https://academic.oup.com/jjco/article/49/8/789/5523680 | - |
dc.subject.keyword | biomarker | - |
dc.subject.keyword | ovarian cancer | - |
dc.subject.keyword | platinum-resistant | - |
dc.subject.keyword | targeted therapy | - |
dc.subject.keyword | umbrella study | - |
dc.contributor.alternativeName | Kim, Sung Hoon | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 789 | - |
dc.citation.endPage | 792 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.49(8) : 789-792, 2019 | - |
dc.identifier.rimsid | 63927 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.